title: Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials.
abstract: OBJECTIVE
  The prognostic impact of complete response (CR) achievement in multiple myeloma (MM) has been shown mostly in the context of autologous stem-cell transplantation. Other levels of response have been defined because, even with high-dose therapy, CR is a relatively rare event. The purpose of this study was to analyze the prognostic impact of very good partial response (VGPR) in patients treated with high-dose therapy.
  
  
  METHODS
  All patients were included in the Intergroupe Francophone du Myelome 99-02 and 99-04 trials and treated with vincristine, doxorubicin, and dexamethasone (VAD) induction therapy followed by double autologous stem-cell transplantation (ASCT). Best post-ASCT response assessment was available for 802 patients.
  
  
  RESULTS
  With a median follow-up of 67 months, median event-free survival (EFS) and 5-year EFS were 42 months and 34%, respectively, for 405 patients who achieved at least VGPR after ASCT versus 32 months and 26% in 288 patients who achieved only partial remission (P = .005). Five-year overall survival (OS) was significantly superior in patients achieving at least VGPR (74% v 61% P = .0017). In multivariate analysis, achievement of less than VGPR was an independent factor predicting shorter EFS and OS. Response to VAD had no impact on EFS and OS. The impact of VGPR achievement on EFS and OS was significant in patients with International Staging System stages 2 to 3 and for patients with poor-risk cytogenetics t(4;14) or del(17p).
  
  
  CONCLUSIONS
  In the context of ASCT, achievement of at least VGPR is a simple prognostic factor that has importance in intermediate and high-risk MM and can be informative in more patients than CR.
authors.affiliation: Centre René Gauducheau Bd Jacques Monod 44850 St Herblain, Nantes, France. jl-harousseau@nantes.fnclcc.fr
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Harousseau
authors.forename: Herve
authors.initials: H
authors.lastname: Avet-Loiseau
authors.forename: Michel
authors.initials: M
authors.lastname: Attal
authors.forename: Catherine
authors.initials: C
authors.lastname: Charbonnel
authors.forename: Frederic
authors.initials: F
authors.lastname: Garban
authors.forename: Cyrille
authors.initials: C
authors.lastname: Hulin
authors.forename: Mauricette
authors.initials: M
authors.lastname: Michallet
authors.forename: Thierry
authors.initials: T
authors.lastname: Facon
authors.forename: Laurent
authors.initials: L
authors.lastname: Garderet
authors.forename: Gerald
authors.initials: G
authors.lastname: Marit
authors.forename: Nicolas
authors.initials: N
authors.lastname: Ketterer
authors.forename: Thierry
authors.initials: T
authors.lastname: Lamy
authors.forename: Laurent
authors.initials: L
authors.lastname: Voillat
authors.forename: Francois
authors.initials: F
authors.lastname: Guilhot
authors.forename: Chantal
authors.initials: C
authors.lastname: Doyen
authors.forename: Claire
authors.initials: C
authors.lastname: Mathiot
authors.forename: Philippe
authors.initials: P
authors.lastname: Moreau
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003907:Dexamethasone / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D011379:Prognosis; D012074:Remission Induction; D015996:Survival Rate; D014182:Transplantation, Autologous; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin